GLP1R and hydrops fetalis: However, due to missing safety data and the modest benefit of GLP-1-RAs over placebo on HHF, none of the cardiology societies of Europe and the US recommend treatment of T2D individuals with GLP-1-RAs in order to reduce the HF risk [15, 18, 22, 98].